Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
Clinical trial NCT05846750 · RECRUITING
Trial details
- NCT number
- NCT05846750
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-01
- Primary completion
- 2026-05-31
- Enrollment
- 59
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.